Novo Nordisk A/S (Novo Nordisk A/S) Debt-to-Equity

: 0.25 (As of Dec. 2023)

View and export this data going back to 1981. Start your Free Trial

Novo Nordisk A/S's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $948 Mil. Novo Nordisk A/S's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $3,003 Mil. Novo Nordisk A/S's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $15,591 Mil. Novo Nordisk A/S's debt to equity for the quarter that ended in Dec. 2023 was 0.25.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Novo Nordisk A/S's Debt-to-Equity or its related term are showing as below:

NVO' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.06 Max: 0.38
Current: 0.25

During the past 13 years, the highest Debt-to-Equity Ratio of Novo Nordisk A/S was 0.38. The lowest was 0.01. And the median was 0.06.

NVO's Debt-to-Equity is ranked worse than
61.29% of 1072 companies
in the Biotechnology industry
Industry Median: 0.145 vs NVO: 0.25

Novo Nordisk A/S Debt-to-Equity Historical Data

The historical data trend for Novo Nordisk A/S's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk A/S Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

0.08

0.16

0.38

0.31

0.25

Novo Nordisk A/S Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity																0.31	0.32	0.28	0.29	0.25

Competitive Comparison

For the Biotechnology subindustry, Novo Nordisk A/S's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Novo Nordisk A/S Debt-to-Equity Distribution

For the Biotechnology industry and Healthcare sector, Novo Nordisk A/S's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Novo Nordisk A/S's Debt-to-Equity falls into.

Novo Nordisk A/S Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Novo Nordisk A/S's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(947.797	+	3003.453)	/	15590.946
	=	0.25

Novo Nordisk A/S's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(947.797	+	3003.453)	/	15590.946
	=	0.25

Novo Nordisk A/S (NYSE:NVO) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Novo Nordisk A/S Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Novo Nordisk A/S's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Novo Nordisk A/S (Novo Nordisk A/S) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novo Nordisk A/S (NYSE:NVO) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

NONOF:USA NOVOB:Mexico NVO:Mexico NOVOBc:UK 0QIU:UK NOVO B:Denmark NOV:Germany NOV:Germany NOVA:Germany NOV:Germany NOV:Germany NOVA:Germany N1VO34:Brazil NNO2:Austria

Address

Novo Alle 1, Bagsvaerd, DNK, DK-2880

Website

https://www.novonordisk.com

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.